Drug Information

Drug (ID: DG01747) and It's Reported Resistant Information

Name	Encorafenib/Cetuximab
Synonyms	Encorafenib/Cetuximab Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Colorectal cancer [ICD-11: 2B91]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)		Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF)			[1]
Molecule Alteration	Missense mutation	p.V600X (c.1798_1799)	Molecule Info
Sensitive Disease	Colorectal cancer [ICD-11: 2B91.1]		Disease Info
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	MAPK signaling pathway	Inhibition	hsa04010
Mechanism Description	Concomitant inhibition leads to sustained suppression of MAPK signaling resulting in reduced cell proliferation and increased antitumor activity.

References

Ref 1	A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal CancerCancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.